Replimune faces November 5 results: Replimune stock has USD 1.1 billion value

Published on 10/20/2026 at 21:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Replimune's Nasdaq range is USD 1.50 to USD 16.33 on October 20, 2026. Replimune stock costs EUR 10.28 on October 20, 2026 at Lang & Schwarz.

Reporting dates and price range

Replimune Group has an estimated earnings date of November 5, 2026, before the market opens.
The Nasdaq price range ran from USD 1.50 to USD 16.33 on October 19, 2026.
Replimune stock costs EUR 10.28 at Lang & Schwarz on October 20, 2026 at 9:04 p.m. CEST.

REPL, US76029N1063, Illustration mit AI erstellt.

Replimune Group (ISIN US76029N1063) has an estimated earnings date of November 5, 2026, before the market opens, according to MarketBeat. The company stock was trading at EUR 10.28 at Lang & Schwarz on October 20, 2026 at 9:04 p.m. CEST.

Price range remains wide

Replimune's Nasdaq quotation closed at USD 10.86 on October 19, 2026. The same dated quotation showed a 52-week range of USD 1.50 to USD 16.33, placing the latest US close 33.50 percent below the yearly high.

Market capitalization stood at USD 1.1 billion as of October 20, 2026. Replimune is a clinical-stage biotechnology company, so the next earnings release matters more for investors than a conventional profit multiple.

November brings two reporting dates

MarketBeat lists November 5, 2026, as the estimated announcement date for the second quarter of fiscal 2027, with an expected loss of USD 0.7840 per share and revenue of USD 1.00 million. The same page lists an earnings call for November 13, 2026, at 9:30 a.m. ET.

The most recent company update on Replimune Group said on October 1, 2026, that TUDRIQEV was available in the United States for advanced melanoma. That commercial milestone leaves the November report as the next scheduled point for operating detail.

Pipeline execution stays central

Replimune develops oncolytic immunotherapies built around genetically engineered viruses intended to destroy tumor cells and stimulate a broader immune response. The company operates in biotechnology rather than an established commercial drug portfolio, making regulatory progress and treatment adoption central to the investment case.

Euro quotation sets the frame

At Lang & Schwarz, Replimune stock was trading at EUR 10.28 on October 20, 2026 at 9:04 p.m. CEST. The quotation is an intraday euro indication, while the Nasdaq reference close was USD 10.86 on October 19, 2026.

The further course of trading is shown by the continuously updated real-time quote of Replimune stock.